Geriatrics

Scientists in the United Kingdom believe they have found a way to deliver new ophthalmologic drugs in eyedrop form.

Chinese research highlights potential benefits of stem cell therapies and gene-editing technology.

A new gene therapy tested the efficacy of injecting a virus into the eye.

Serum levels of ubiquitin and proteasome correlated well with uveitis score.

Ranibizumab can now treat patients with all forms of diabetic retinopathy.

Reassurance should focus on success rates and low risk of serious problems.

AMD negatively affected vision-specific function in Chinese but not others.

Glaucoma surgery 2.5 times more likely after 7 or more shots in a year than after 3.

Acute intraocular inflammation was less common for ranibizumab than aflibercept.

Perceived Stress Scale worked well in assessing stress levels of AMD patients.

Two-year retrospective study indicates need to tailor treatment strategy.

DME patients in non-interventional studies notably older than in RCTs.

Researchers compared aflibercept, bevacizumab, and ranibizumab injections.

Of the 3 regimens, monthly aflibercept produced the greatest gain in mean BCVA.

Uveitis patients age ≥55 years are less likely to have large drusen than others.

Screen for morphological risk factors for an RPE tear before each injection.

Researchers find gap in antioxidant enzymes between AMD patients and controls.

Whether injected monthly or according to a TREX regimen, ranibizumab did not have a statistically significant effect on the development of new macular atrophy in eyes with neovascular AMD.

At the one-month follow-up exam, only 7% were functional non-responders, half of whom were reclassified as responders at 6-month follow-up.

In a new study, stroke occurred in 6.6% of the ranibizumab-treated group, compared with 7.0% of the controls matched by sociodemographic factors and comorbidities and 6.7% of the controls matched by sociodemographic factors only. These differences were not statistically significant.

The billion-dollar combination of pegpleranib and ranibizumab failed to meet primary endpoints in studies for the treatment of age-related macular degeneration.

Age-related macular degeneration, the leading cause of blindness in the developed world, has long been linked to diet and obesity. Recently, we came closer to understanding just exactly why that is.

A recent study joins an ever-deepening well of data about the health benefits of the Mediterranean diet, including its risk-reduction potential for age-related macular degeneration. AMD is the leading cause of blindness in the developed world.

As with most surgical advances, new potential procedures in ophthalmology pose their fair share of risks. However, if those risks can be overcome the rewards to patients can make a significant difference in their quality of life.

As a retinal implant, the ARGUS II technology has shown early benefits for patients with retinitis pigmentosa. A new study from the United Kingdom is examining its benefits in patients with the dry form of age related macular degeneration.

As with all new technologies for surgical procedures, there will be questions to be answered about the safety for hypersonic vitrectomy. While human trials have not started yet, there are good indications in cadaveric and animal studies.

Medical technology is constantly evolving across fields, and ophthalmology is no exception. A new hypersonic vitrectomy device is currently in development and could be on the market in 2017.

Researchers are getting closer to understanding the pathogenesis of one type of age-related macular degeneration.

Research using mouse models demonstrated that a high-fat diet increased intestinal permeability, which led to increases in circulating and local inflammatory cytokines, and increased choroidal neovascularization.

Treatment with recombinant adeno-associated virus vector gene-therapy was shown to be safe and potentially effective in a small test group of patients with neovascular age-related macular degeneration.